We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

SynAct Pharma AB (SYNACT) NPV

Sell:9.29 SEK Buy:9.39 SEK Change: 0.015 SEK (0.16%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.29 SEK
Buy:9.39 SEK
Change: 0.015 SEK (0.16%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:9.29 SEK
Buy:9.39 SEK
Change: 0.015 SEK (0.16%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Contact details

Address:
Scheelevagen 2
LUND
22363
Sweden
Telephone:
+ ()
Website:
https://synactpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SYNACT
ISIN:
SE0008241491
Market cap:
382.61 million SEK
Shares in issue:
41.30 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Anders Kronborg
    Chairman of the Board
  • Jeppe Oevlesen
    Chief Executive Officer, Director
  • Bjoern Westberg
    Chief Financial Officer
  • Thomas Boesen
    Chief Operating Officer
  • Thomas Jonassen
    Chief Scientific Officer
  • James Knight
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.